India Pharma Outlook Team | Tuesday, 14 April 2026
India is set to overhaul how biosimilar drugs are approved, with regulators proposing a major shift that could cut costs, speed up access, and reshape the pharmaceutical landscape.
According to a report, DGCI is working on new biosimilar guidelines that would ease long-standing requirements around bioequivalence studies—one of the most time-consuming and expensive parts of drug development.
Speaking at the ninth edition of India Pharma 2026, Dr Rajeev Raghuvanshi informed that based on recommendations received on the draft issued last year "the final guidelines will reduce the need for separate bioequivalence studies and rely more heavily on characterization to demonstrate equivalence with the innovator product."
India moves to relax biosimilar testing rules
The proposal comes from the office of the Drugs Controller General of India (DCGI), operating under the Central Drugs Standard Control Organization (CDSCO).
Under the revised framework, companies developing biosimilars may no longer need to conduct extensive human bioequivalence studies in every case. Instead, regulators are considering a model that allows waivers or reduced clinical requirements if a drug demonstrates strong similarity through advanced laboratory analysis.
This marks a clear departure from earlier rules, where human trials were often mandatory even when analytical data was robust.
Also Read: New Dynamics of Drug Distribution, Free Medicine Schemes in India
Shift toward science-led approvals
The new guidelines place greater weight on:
This approach reflects global regulatory trends, where advances in biotechnology now allow scientists to detect even minor differences between biologic drugs without relying heavily on human trials.
Experts say this could significantly streamline the approval process without compromising scientific rigor—if implemented carefully.
Faster development, lower costs
Bioequivalence studies are not just complex—they are expensive and slow. By easing these requirements, the regulator aims to:
For Indian pharmaceutical firms, this could unlock faster pathways to both domestic and global markets, especially in high-demand therapy areas like oncology and diabetes.
Impact on patients and access
The ripple effect could be significant for patients. Biosimilars are typically more affordable versions of costly biologic drugs. With easier approvals:
India already plays a key role in the global generics market. These changes could strengthen its position in the more complex and high-value biosimilars segment.
Concerns around safety remain
Despite the potential benefits, the move raises important questions. Reducing clinical testing requirements can spark concerns about whether safety and efficacy are being fully validated.
Regulators, however, argue that this is not about lowering standards. Instead, it reflects a shift toward modern scientific methods that can deliver the same level of confidence through more precise tools.
A turning point for India’s pharma sector
The proposed guidelines signal a broader transformation in how India regulates advanced medicines. By moving away from a one-size-fits-all clinical model, the country is aligning itself with global best practices while trying to balance innovation, safety, and access.
If implemented effectively, the changes could redefine how quickly and affordably critical biologic treatments reach millions of patients.
.jpg)
